An open-label, long-term, phase III extension trial of duloxetine in Japanese patients with fibromyalgia

作者：Murakami Masato; Osada Kenichi; Ichibayashi Hisao; Mizuno Hiromichi; Ochiai Toshimitsu; Ishida Mitsuhiro; Alev Levent; Nishioka Kusuki^*

来源：Modern Rheumatology, 2017, 27(4): 688-695.

DOI：10.1080/14397595.2016.1245237

• Duloxetine
• Fibromyalgia
• Japan
• Long-term safety
• Open-label

Objectives: We aimed to evaluate the long-term safety and efficacy of duloxetine 60mg in Japanese patients with fibromyalgia enrolled from a preceding randomized, placebo-controlled, phase III duloxetine trial.
Methods: This was a long-term, open-label extension study. Patients received oral duloxetine once daily at a dose of 20mg for 1week, followed by 40mg for 1week, and then 60mg for 48weeks. The primary outcome was the frequency of adverse events (AEs) and adverse drug reactions (ADRs) of duloxetine. Efficacy and health outcomes were assessed.
Results: In total, 149 patients were enrolled from the preceding study. The median length of treatment was 364.0days. The incidence of AEs and ADRs was 92.6 and 63.8%, respectively. ADRs occurring at an incidence of 5% were somnolence, constipation, nausea, weight increase, thirst, and malaise. The proportion of patients with mild, moderate, and severe AEs was 80.5, 10.1, and 2.0%. There were no serious treatment-related AEs in this study. The Brief Pain Inventory average pain score improved at all time-points compared with baseline (mean changestandard deviation at Week 50 was-1.31 +/- 1.70).
Conclusions: Duloxetine was safe and effective in the long-term treatment of Japanese patients with fibromyalgia.

• 出版日期2017
• 单位河北医科大学